@article{0c986a44c5e24730b9cbe1ecf9a024e5,
title = "Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis",
abstract = "We present here results at 60 months (M), from the extension component of a phase 2, randomized, placebo-controlled, double-blind, six-month study evaluating oral fingolimod (1.25 mg or 5 mg daily) in relapsing multiple sclerosis. Placebo patients from the core study were re-randomized to fingolimod 1.25 mg or 5 mg in the extension. All patients received 1.25 mg fingolimod after the M24 visit. A total of 140/281 (49.8%) patients completed M60. Fingolimod treatment was associated with a low annualized relapse rate (0.2 relapses/ year), low MRI activity, and a modest rate of disability progression in those treated for five years. No new safety issues were reported.",
keywords = "Disease-modifying therapy, Fingolimod, Long term, Phase 2, Relapsing-remitting multiple sclerosis, Sphingosine 1-phosphate receptor modulator",
author = "G. Izquierdo and P. O'Connor and X. Montalban and {Von Rosenstiel}, P. and M. Cremer and {De Vera}, A. and N. Sfikas and G. Francis and Radue, {E. W.} and Ludwig Kappos",
note = "Funding Information: P O{\textquoteright}Connor has received either personal compensation (for consulting, serving on a scientific advisory board, or speaking) or financial support for scholarly activities from pharmaceutical companies that develop products for MS, including Actelion, Biogen Idec., Celgene, Sanofi-Aventis, EMD Serono, Abbott Labs, Teva Pharmaceuticals, Bayer, Bio MS, Genentech, Lilly, Roche and Novartis. He has received consultation fees from the MS Society of Canada. Grant support has been received from the MS Society of Canada, the National Institutes of Health (NIH) and Direct MS. Funding Information: This study was funded by Novartis Pharma AG; Clinicaltrials.gov : NCT00785083.",
year = "2014",
month = jun,
doi = "10.1177/1352458513513059",
language = "English",
volume = "20",
pages = "877--881",
journal = "Multiple Sclerosis Journal",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "7",
}